Overview
- Plaintiffs have filed a securities class action and two law firms are soliciting Zoetis shareholders to join the case and move for lead-plaintiff status.
- The suit says defendants falsely touted growing market share, strong veterinarian adoption, and accelerating sales for companion-animal products.
- The complaint singles out three product issues: Librela prescriptions weakened after FDA safety warnings, Simparica Trio lost share to a lower-priced rival, and Apoquel and Cytopoint faced erosion from a new competitor.
- The alleged Class Period runs from January 14, 2025 through May 6, 2026 and the deadline to seek lead-plaintiff status is July 27, 2026; no class has been certified and the case is at an early procedural stage.
- If investors join, they may seek damages on a contingency-fee basis and the case could produce discovery into Zoetis’ product disclosures, vet prescribing trends, and the impact of FDA communications on adoption.